Περίληψη:
Erdheim–Chester disease (ECD) is a rare clonal histiocytic neoplasm with less than 1200 documented cases to date. The disease is life-threatening and difficult to recognize, although increasing awareness as well as the integration of clinical, imaging, pathology information, and genetic studies have led to a recent exponential increase in new reported cases. ECD affects multiple organs and systems, including skeletal, neurologic, and cardiovascular. Pulmonary, retroperitoneal, and cutaneous lesions have also been reported in various combinations. Until the discovery that more than half of ECD patients harbor the BRAF-V600E mutation or other mutations in the mitogen-activated protein kinase (MAPK) and RAS pathways, Interferon-a was the first-line treatment. Nowadays BRAF and MEK-inhibitors targeted therapies are the mainstay of treatment. Ophthalmologic involvement occurs in 25% −30% of ECD cases, usually in the form of orbital involvement presenting with exophthalmos and ophthalmoplegia. Other ophthalmologic manifestations include palpebral xanthelasmas, anterior uveitis and vitritis, optic disk edema, choroidal infiltration, recurrent serous retinal detachment, retinal drusen–like deposits and retinal pigment epithelial changes. ECD patients can also present with ocular symptoms as a result of adverse effects of the treatment regimens. In some cases with smoldering or protean symptoms, the emergence of eye manifestations triggered the diagnosis. Ophthalmologists have to be aware of the disease, recognize the constellation of ECD symptoms, and contribute to the diagnosis, treatment, and follow-up of ECD patients. © 2021 Elsevier Inc.
Συγγραφείς:
Kanakis, M.
Petrou, P.
Lourida, G.
Georgalas, I.
Λέξεις-κλειδιά:
B Raf kinase; B Raf kinase inhibitor; biological product; corticosteroid; everolimus; interferon; interferon a; mitogen activated protein kinase; mitogen activated protein kinase kinase inhibitor; Ras protein; sirolimus; unclassified drug, awareness; cell infiltration; chemotherapy; combination drug therapy; drusen; Erdheim Chester disease; exophthalmos; eye disease; follow up; gene mutation; genetic analysis; histopathology; human; iridocyclitis; MAPK signaling; ophthalmoplegia; palpebral xanthelasma; papilledema; prognosis; radiography; retina detachment; retina tear; Review; treatment response; vitritis
